What Not to Take With Retatrutide

Retatrutide is an investigational triple hormone receptor agonist being studied in clinical trials for obesity and type 2 diabetes, with no UK marketing authorisation. Understanding what not to take with retatrutide is important for trial participants and clinicians, as formal interaction data are limited to trial protocols rather than a licensed product label. This article outlines the drug classes, medical conditions and safety signals relevant to retatrutide based on available trial-phase evidence, and explains why access outside an authorised clinical trial is not possible in the UK.

What is retatrutide and what is its current status in the UK?

Retatrutide holds no UK marketing authorisation and can only be accessed within an authorised clinical trial; it is not available through a GP, pharmacy or online clinic.

Retatrutide holds no marketing authorisation in the UK or anywhere else, and it can be accessed only within an authorised clinical trial.^[1] It is an investigational medicine being studied as a potential treatment for obesity and type 2 diabetes, including in the Phase 3 TRIUMPH and TRANSCEND programmes. Unlike licensed GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro), retatrutide is not available through a GP, a pharmacy or any online clinic outside a formal research setting.

Retatrutide acts on three hormone receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple agonist mechanism distinguishes it pharmacologically from currently licensed dual or single agonists, though what this means for individual patients in routine care cannot be stated until regulatory review is complete.

Because retatrutide is investigational, the MHRA has not issued a Summary of Product Characteristics (SmPC) for it. The interaction and contraindication data available come from clinical trial protocols and published trial reports rather than from a licensed product label. Any information about what not to take with retatrutide must therefore be understood in that context: it reflects trial-phase findings, not a finalised regulatory assessment. No UK authorisation date can be given, and no pathway to obtaining retatrutide outside a trial exists. If you are interested in licensed weight-management options, a GP can discuss what is currently available.

What drugs and substances may interact with retatrutide?

No formally approved interaction data exist; precautionary concerns based on GLP-1 class experience include narrow therapeutic index drugs, insulin, sulfonylureas, alcohol and oral contraceptives.

No formally approved interaction data exist for retatrutide, because the medicine has not received a marketing authorisation and no SmPC has been issued by the MHRA. What is known comes from the pharmacological class to which retatrutide belongs and from the trial protocols of the TRIUMPH and TRANSCEND programmes, which excluded or monitored participants taking certain concomitant medicines. The points below are therefore precautionary extrapolations from class experience, not established interactions for this specific agent.

GLP-1 receptor agonists as a class slow gastric emptying, and retatrutide is expected to share this effect based on its mechanism. Slowed gastric emptying can alter the absorption rate of orally administered medicines. This is particularly relevant for drugs with a narrow therapeutic index, such as warfarin and certain antiepileptics, where even modest changes in absorption timing may affect clinical outcomes. Patients taking such medicines in any trial setting would require closer monitoring; these are monitoring considerations rather than confirmed interactions with retatrutide specifically.

Medicines that lower blood glucose, principally insulin and sulfonylureas, carry an increased risk of hypoglycaemia when combined with agents that also reduce glucose levels. Trial participants using insulin alongside investigational GLP-1 class agents typically have their insulin doses reviewed and adjusted under close supervision. Alcohol can compound hypoglycaemia risk and may also worsen gastrointestinal side effects that are common with this drug class.

Concomitant use of retatrutide with other incretin-based therapies is generally excluded in trial protocols and should not be attempted outside an authorised study.

For oral contraceptives, licensed GLP-1 medicines carry specific precautions: the tirzepatide (Mounjaro) SmPC, for example, advises additional contraceptive precautions for four weeks after initiation and for four weeks after each dose escalation, because slowed gastric emptying may reduce oral contraceptive absorption.^[9][10] Trial protocols for retatrutide set out their own contraceptive requirements, and participants should follow those instructions precisely.

If a trial participant requires surgery or a procedure involving anaesthesia, they should inform the trial team and the anaesthetist in advance. GLP-1 class medicines have been associated with a risk of pulmonary aspiration under anaesthesia due to delayed gastric emptying, and the MHRA has issued guidance on this.^[11] Management, including whether to withhold a dose before a procedure, must follow the trial protocol.

Anyone enrolled in a retatrutide trial should disclose all medicines, supplements and herbal products to the trial team, who are responsible for managing interactions under the study protocol.

Are there any medical conditions that make retatrutide unsafe?

Trial exclusion criteria include certain thyroid conditions, pancreatitis history, severe cardiovascular disease, significant renal or hepatic impairment, pregnancy and breastfeeding.

Clinical trial protocols for retatrutide, including those within the TRIUMPH and TRANSCEND programmes, have defined exclusion criteria that reflect conditions considered incompatible with safe participation. These exclusion criteria are not the same as a licensed contraindication list, but they indicate the populations in whom the medicine has not been studied and where risk-benefit cannot currently be assessed. Any assessment of whether a specific medical condition makes retatrutide unsafe must be made by the trial team within the authorised study protocol, not by a GP or independent prescriber outside that setting.

Participants with a personal or family history of certain thyroid conditions have generally been excluded from retatrutide trials. This reflects a theoretical concern about C-cell effects seen in animal studies with GLP-1 class medicines; it is a trial exclusion criterion, not a confirmed UK contraindication. Participants with severe cardiovascular disease, active malignancy, or significant renal or hepatic impairment have also typically been excluded. People with a history of pancreatitis have been excluded given that acute pancreatitis is a recognised safety signal across the GLP-1 receptor agonist class, including post-marketing reports of necrotising pancreatitis with licensed medicines.^[13][14]

Severe gastrointestinal motility disorders, such as gastroparesis, and a history of gallbladder disease are commonly excluded or require caution with GLP-1 class agents based on class experience, and this is likely to be reflected in retatrutide trial protocols.

For people with diabetes, GLP-1 class experience includes reports of worsening diabetic retinopathy, particularly in those with pre-proliferative or proliferative disease.^[16][17] This is a class-level signal rather than a confirmed finding specific to retatrutide, but it is relevant to trial screening and monitoring. Anyone with pre-existing retinopathy who is considering trial participation should ensure the trial team is aware.

Pregnancy, breastfeeding and planned pregnancy are exclusion criteria in retatrutide trials. Animal reproductive toxicity studies with GLP-1 class medicines have raised concerns, and the absence of human safety data in pregnancy means participation is not appropriate for those who are pregnant or breastfeeding. Women of childbearing potential enrolled in trials are required to use effective contraception throughout the study period, with specific requirements set out in each trial's protocol.

People with a history of eating disorders, active suicidal ideation, or certain psychiatric conditions have also been excluded from some trial cohorts, reflecting the broader monitoring requirements of investigational medicine studies.

What side effects and safety signals have clinical trials reported?

The most commonly reported adverse events are gastrointestinal, including nausea, vomiting and diarrhoea; acute pancreatitis, hypoglycaemia and heart rate increases have also been observed in trial data.

Clinical trials of retatrutide, including data from the TRIUMPH and TRANSCEND programmes, have reported a side-effect profile broadly consistent with the GLP-1 receptor agonist class, though the glucagon receptor component may contribute additional effects. The most commonly reported adverse events have been gastrointestinal in nature, including nausea, vomiting, diarrhoea and constipation. These effects were generally more frequent during dose escalation and tended to diminish over time in trial participants.

Acute pancreatitis has been reported as a safety signal across the GLP-1 class, including post-marketing reports of necrotising pancreatitis with licensed medicines.^[13][14] Trial participants are monitored for symptoms such as persistent severe abdominal pain radiating to the back. Anyone experiencing such symptoms in a trial setting should contact the trial team immediately. Outside a trial, if someone experiences these symptoms, they should seek urgent assessment via NHS 111 or, if symptoms are severe, attend A&E.

Hypoglycaemia has been reported, particularly in participants also using insulin or sulfonylureas. Heart rate increases have been observed with retatrutide in trial data, and cardiovascular monitoring has formed part of the trial protocols.^[4][5] Injection-site reactions, including redness and discomfort, have also been noted.

Gallbladder-related events and dehydration-related effects on renal function are recognised class signals with GLP-1 medicines.^[14][15] Trial protocols include monitoring for these, and participants should report any symptoms such as severe upper abdominal pain, jaundice, or significant reduction in urine output to the trial team promptly.

Trial participants should carry their trial identification and study team contact details whenever they attend any healthcare appointment, including A&E or urgent care. Informing emergency clinicians of trial participation allows them to take the investigational medicine into account when making treatment decisions.

Because retatrutide is investigational, suspected adverse events in trial participants must be reported to the trial team under the study protocol. Suspected side effects can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Anything sold online as retatrutide is not a licensed product and may be falsified or counterfeit, carrying unknown and potentially serious risks. No legitimate supply of retatrutide exists outside an authorised clinical trial.

Scientific References

1. EMA decision on paediatric investigation plan for retatrutide (P-0336-2024).
2. Retatrutide for the treatment of obesity, obstructive sleep apnoea and related conditions: TRIUMPH programme.
3. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease.
4. Triple–Hormone-Receptor Agonist Retatrutide for Obesity.
5. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.
6. A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.
7. Opioid Toxicity Associated With Tirzepatide in a Patient on Chronic Oral Morphine.
8. Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review.
9. Mounjaro (tirzepatide) EPAR product information.
10. Women on 'skinny jabs' must use effective contraception, MHRA urges in latest guidance.
11. GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation.
12. Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents.
13. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
14. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
15. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
16. Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations.
17. GLP-1 Receptor Agonists and Sight-Threatening Diabetic Retinopathy.
18. Semaglutide-eye-catching results.
19. Effect of GLP1 Agonists on Reproduction.
20. The Yellow Card scheme: guidance for healthcare professionals, patients and the public.

Frequently Asked Questions